Dr Reddy's Laboratories is set to launch 30 more products in the US market this year, said Saumen Chakraborty, President, CFO & Global Head-IT at DRL, after the company beat estimates in the second quarter with growth seen across geographies.
“We have seen a good number of launches in the first half of FY21,” said Chakraborty.
“One of the key factors which contributes to the growth is new product launch. Since we have started doing well on executing our launches, that’s contributing to our growth. Potentials are there in multiple markets whether it is in India, emerging markets, China and also in the US and Europe,” added Chakraborty.
On API, he said, “Active pharmaceutical ingredient (API) and service business has high growth potential.”
Speaking about vaccine trials, Chakraborty said phase-II and phase-III trials of ‘Sputnik V’ vaccine are underway.
For more, watch the video